Several biotechnology and pharmaceutical names posted notable gains in after-hours trading on Monday, driven by clinical trial updates, regulatory progress, and investor anticipation ahead of key data releases.Alumis Inc. (ALMS) surged 17.33% to $9.75, adding$1.44 after announcing that topline data from its Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis will be reported on January 6, 2026. The company also confirmed it will host a conference ...